New-onset Type 1 Diabetes after COVID-19 mRNA Vaccination

• Published in: Internal Medicine Vol. 61; no. 8; pp. 1197 - 1200
• Main Authors: Yano, Masahiro, Morioka, Tomoaki, Natsuki, Yuka, Sasaki, Keyaki, Kakutani, Yoshinori, Ochi, Akinobu, Yamazaki, Yuko, Shoji, Tetsuo, Emoto, Masanori
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 15.04.2022; Japan Science and Technology Agency
• Subjects: Autoantibodies; Autoimmunity; Case Report; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - genetics; Drb1 protein; Female; Haplotypes; Histocompatibility antigen HLA; Humans; hyperglycemia; Immunization; Insulin; Insulin secretion; Internal medicine; Ketoacidosis; Middle Aged; mRNA; mRNA vaccine; RNA, Messenger - genetics; SARS-CoV-2; Thyroid; Tissue typing; type 1 diabetes; Vaccination - adverse effects; Vaccines; COVID-19; hyperglycemia; SARS-CoV-2; type 1 diabetes; autoimmunity; mRNA vaccine
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.9004-21

During the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is critical to ensure the safety of COVID-19 vaccines. We herein report a 51-year-old Japanese woman who developed acute-onset type 1 diabetes with diabetic ketoacidosis six weeks after receiving the first dose of a COVID-19 messenger ribonucleic acid (mRNA) vaccine. Laboratory tests indicated exhaustion of endogenous insulin secretion, a positive result for insulin autoantibody, and latent thyroid autoimmunity. Human leukocyte antigen typing was homozygous for DRB1*09:01-DQB1*03:03 haplotypes. This case suggests that COVID-19 vaccination can induce type 1 diabetes in some individuals with a genetic predisposition.